Galapagos

Generaal De Wittelaan L 11A3
2800 Mechelen
BE
Galapagos
Foundation date
30/06/1999
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera
Friday February 3rd 2023
Read more
-
Weber joins Vivactis Group to reinforce its Market Access capabilities
Thursday February 2nd 2023
Read more
-
Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health
Thursday February 2nd 2023
Read more
Jobs
More jobs-
-
02/02/23
Flemish Brabant
Research associate to support the Single Cell & Microfluidics Expertise unit
Permanent
VIB -